, Volume 41, Issue 1, pp 199–202

Could anti-HCV treatment prevent recurrence of hepatocellular carcinoma in HIV-infected patients? Two case reports

  • G. Cenderello
  • E. Pontali
  • G. Cassola
  • A. Torresin
Brief Report


Highly active antiretroviral therapy (HAART) has proven long-term efficacy in human immunodeficiency virus (HIV) infection. Combination therapy with pegylated interferon and ribavirin has become the standard of care in patients with both hepatitis C virus (HCV) chronic hepatitis and HIV/HCV co-infection. Data on the safety and efficacy of combination therapy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) is scarce and even more so in HIV/HCV co-infected subjects. We report the successful administration of both HAART and anti-HCV therapies in two HIV/HCV co-infected patients after HCC eradication. These encouraging results might argue for the feasibility of an aggressive approach in the management of co-infected patients with HCC.


  1. 1.
    Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–60.PubMedCrossRefGoogle Scholar
  3. 3.
    Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999;160:659–65.PubMedGoogle Scholar
  4. 4.
    Floridia M, Massella M, Bucciardini R, et al. Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm3). HIV Clin Trials. 2000;1:9–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Mocroft A, Soriano V, Rockstroh J, et al.; EuroSIDA Study Group. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS. 2005;19,:2117–25.PubMedCrossRefGoogle Scholar
  6. 6.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073–89.PubMedCrossRefGoogle Scholar
  8. 8.
    European AIDS Clinical Society (EACS): Clinical management and treatment of chronic hepatitis B & C in HIV infected adults. 2009. Accessed 4 Sept 2011.
  9. 9.
    Macdonald DC, Nelson M, Bower M, et al. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol. 2008;14:1657–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Hino K, Okita K. Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C. J Antimicrob Chemother. 2004;53:19–22.PubMedCrossRefGoogle Scholar
  11. 11.
    Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S294–302.PubMedCrossRefGoogle Scholar
  12. 12.
    Hung CH, Lee CM, Wang JH, et al. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol. 2005;20:1553–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Omata M, Yoshida H, Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol. 2005;3(10 Suppl 2):S141–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis. 2010;42:81–91.CrossRefGoogle Scholar
  15. 15.
    Huang JF, Yu ML, Huang CF, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis C patients with hepatocellular carcinoma post curative therapies—a multicenter prospective trial. J Hepatol. 2011;54:216–26.CrossRefGoogle Scholar
  16. 16.
    Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122:1609–19.PubMedCrossRefGoogle Scholar
  17. 17.
    Pineda JA, Romero-Gómez M, Díaz-García F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779–89.PubMedCrossRefGoogle Scholar
  18. 18.
    Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18:2285–93.PubMedCrossRefGoogle Scholar
  19. 19.
    Bräu N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527–37.PubMedCrossRefGoogle Scholar
  20. 20.
    García-Samaniego J, Rodríguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol. 2001;96:179–83.PubMedGoogle Scholar
  21. 21.
    Berretta M, Garlassi E, Cacopardo B, et al. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist. 2011;16:1258–69.PubMedCrossRefGoogle Scholar
  22. 22.
    Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105–14.PubMedGoogle Scholar
  23. 23.
    Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 2001;134:963–7.PubMedGoogle Scholar
  25. 25.
    Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138:299–306.PubMedGoogle Scholar
  26. 26.
    Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 2004;100:376–82.PubMedCrossRefGoogle Scholar
  27. 27.
    Kubo S, Nishiguchi S, Hirohashi K, et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002;89:418–22.PubMedCrossRefGoogle Scholar
  28. 28.
    International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet. 1998;351:1535–9.CrossRefGoogle Scholar
  29. 29.
    Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–54.PubMedCrossRefGoogle Scholar
  30. 30.
    Wright TL. Antiviral therapy and primary and secondary prevention of hepatocellular carcinoma. Hepatol Res. 2007;37(Suppl 2):S294–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Ishikawa T. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol. 2008;14:6140–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Abbas Z, Siddiqui AU, Luck NH, et al. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. J Pak Med Assoc. 2008;58:602–7.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • G. Cenderello
    • 1
  • E. Pontali
    • 1
  • G. Cassola
    • 1
  • A. Torresin
    • 1
  1. 1.Department of Infectious DiseasesEO Ospedali GallieraGenoaItaly

Personalised recommendations